Phase 2 Peripheral Neuropathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with Small Fiber Neuropathy (SFN) using a specific set of recognised diagnostic standards (confirm with trial site)
- People whose pain has not responded adequately to at least 2 out of 3 categories of standard first-line pain treatments for at least 6 months before the screening visit
- People whose blood test shows no pre-existing antibodies to a specific virus-based delivery agent called AAV9
Who may not be able to join:
- People who have been using opioid pain medicines for less than 3 months, or whose opioid dose is not stable; if already on a stable dose, the dose must not increase during the study
- People with a known history of alcohol misuse, opioid misuse, or illegal drug use within the 2 years before screening
- People whose urine drug test at screening or the day before the procedure is positive for non-prescribed substances (including opiates, benzodiazepines, amphetamines, cocaine, barbiturates, or phencyclidine) without investigator approval
- People who use cannabinoids (cannabis-based products)
- People with Fabry's disease, erythromelalgia, neuropathy caused by alcohol or drug toxicity, or a diagnosed channelopathy (a specific type of nerve channel disorder)
- People for whom a spinal fluid procedure (lumbar puncture), general anaesthetic, or sedation would not be safe
- People with certain medical conditions that could make a lumbar puncture unsafe, such as certain brain or spine conditions, bleeding disorders, low platelet counts, or increased pressure in the brain (confirm with trial site for the full list)
- People with a current active viral or bacterial infection
- People who had a serious infection such as pneumonia, blood poisoning, or a brain/nervous system infection within 12 weeks before screening
- People with a clinically significant liver disease or certain abnormal liver blood test results (confirm with trial site for specific values)
- People taking high-dose paracetamol (acetaminophen) above 4 grams per day, unless considered essential by the investigator and liver function is normal
- People taking supplements known to be harmful to the liver during the study period
- People with a history of cancer within the past 5 years — though some exceptions may apply, including certain fully treated skin cancers, non-spreading prostate cancer, and fully treated early-stage breast cancer where the person has been stable for at least 6 months (confirm with trial site)
- People who have previously had a bone marrow transplant, stem cell transplant, or solid organ transplant
- People who have previously received any gene therapy or cell therapy
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Medical Monitor, Sangamo Therapeutics Inc.
Phone: 510-307-7266
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence and severity of treatment emergent adverse events (TEAEs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.